Ocumension Therapeutics (HK:1477) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ocumension Therapeutics has entered into a strategic partnership with Alcon, acquiring rights to manufacture and commercialize certain ophthalmic products in China. They will issue 139,159,664 new shares to Alcon Pharma, representing a significant stake in the company post-transaction. The deal, valued at HK$1,020.04 million based on the current share price, is considered a very substantial acquisition and will require shareholder approval.
For further insights into HK:1477 stock, check out TipRanks’ Stock Analysis page.